Sumitomo Pharma America Doses First Patient With DSP-3077
MARLBOROUGH, Mass., August 12, 2026 Sumitomo Pharma America, Inc. announced that the first patient has received treatment with DSP-3077...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
MARLBOROUGH, Mass., August 12, 2026 Sumitomo Pharma America, Inc. announced that the first patient has received treatment with DSP-3077...
BURLINGTON, Mass., August 12, 2026 Bone Biologics Corporation announced that its rhNELL-1 protein has achieved a validated shelf life...
